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OBJECTIVE
The Liraglutide Effect andAction inDiabetes: Evaluation of Cardiovascular Outcome
Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a
reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who
received theglucagon-likepeptide1 receptor agonist liraglutideversusplacebo. The
mechanisms behind this CV benefit remain unclear. We aimed to identify potential
mediators for the CV benefit observed with liraglutide in the LEADER trial.
RESEARCH DESIGN AND METHODS
We performed exploratory analyses to identify potential mediators of the effect of
liraglutide on major adverse CV events (MACE; composite of CV death, nonfatal
myocardial infarction, or nonfatal stroke) from the following candidates: glycated
hemoglobin (HbA1c), body weight, urinary albumin-to-creatinine ratio (UACR),
confirmed hypoglycemia, sulfonylurea use, insulin use, systolic blood pressure,
and LDL cholesterol. These candidates were selected as CV risk factors on which
liraglutide had an effect in LEADER such that a reduction in CV risk might result. We
used two methods based on a Cox proportional hazards model and the new
Vansteelandt method designed to use all available information from the mediator
and to control for confounding factors.
RESULTS
Analyses using the Cox methods and Vansteelandt method indicated potential
mediation by HbA1c (up to 41% and 83% mediation, respectively) and UACR (up to
29% and 33% mediation, respectively) on the effect of liraglutide on MACE. Me-
diation effects were small for other candidates.
CONCLUSIONS
These analyses identify HbA1c and, to a lesser extent, UACR as potentialmediators
of theCVeffects of liraglutide.Whether either is amarker of anunmeasured factor
or a true mediator remains a key question that invites further investigation.
Liraglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for the
management of hyperglycemia in type 2 diabetes and for reduction of cardiovascular
(CV) risk in patients with type 2 diabetes and clinical CV disease (CVD) (1,2). It is also
approved at a higher dose for the treatment of obesity (3,4). The Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial was
initiated to assess the CV safety of liraglutide in patients with type 2 diabetes and
1University of North Carolina School of Medicine, 
Chapel Hill, NC
2Swansea University Medical School, Swansea, 
U.K.
3KfH Kidney Centre, Munich, Germany 
4Department of Nephrology, Friedrich-Alexander 
University of Erlangen-Nürnberg, Erlangen, Germany 
5Diabetes Center Bochum-Hattingen, St. Josef Hos-
pital (Ruhr-Universität Bochum), Bochum, Germany 
6Cleveland Clinic, Cleveland, OH 
7Department of Medical Statistics, London School 
of Hygiene & Tropical Medicine, London, U.K. 
8School of Public Health, Imperial College London, 
London, U.K.
9AdventHealth Translational Research Institute, 
Orlando, FL
10Novo Nordisk A/S, Søborg, Denmark 
11Lunenfeld-Tanenbaum Research Institute, Mount 
Sinai Hospital, University of Toronto, Toronto, On-
tario, Canada
Corresponding author: John B. Buse, jbuse@med 
.unc.edu
Received 8 November 2019 and accepted 5 April 
2020
This article contains supplementary material online 
at https://doi.org/10.2337/figshare.12106860.
*A complete list of the LEADER Trial investigators 
and members can be found in the supplementary 
material online.
John B. Buse,1 Stephen C. Bain,2
Johannes F.E. Mann,3,4 Michael A. Nauck,5
Steven E. Nissen,6 Stuart Pocock,7
Neil R. Poulter,8 Richard E. Pratley,9
Martin Linder,10 Tea Monk Fries,10
David D. Ørsted,10 and Bernard Zinman,11 on
behalf of the LEADER Trial Investigators*
showed that it reduced the risk of CV
events, all-cause mortality, and renal
events compared with placebo (5,6).
Typical CV risk factors associated with
type 2 diabetes (glycemic control, body
weight, bloodpressure, and lipidprofiles)
are improved by GLP-1 RAs, including
liraglutide (7). During the LEADER trial,
liraglutide reduced glycated hemoglo-
bin (HbA1c) and body weight, along with
small but significant reductions in systolic
blood pressure (6). Liraglutide has also
shownmultiple direct anti-inflammatory
and antiatherosclerotic effects in non-
clinical studies (7,8). Given these numer-
ous effects of GLP-1 RAs, it is a challenge
to pinpoint the relevant mechanisms
underlying the CV benefit of liraglutide
(7,9). Mediation analyses allow investi-
gation of the associations among known,
measured variables, such as the afore-
mentioned risk factors, and outcomes,
but do not necessarily identify causality.
In the present exploratory analyses,
we sought to identify potential media-
tors for the CV benefit observed with
liraglutide using data from the LEADER
trial.We explored thesewith several me-
diation methods, including a new statis-
tical methodology designed to integrate
sequential confounders (a limitation of
existing methods for mediation analysis)
(10).
RESEARCH DESIGN AND METHODS
Trial Design
The double-blind, randomized, placebo-
controlled LEADER trial assessed the
CV safety of liraglutide in the context of
standard care in patients with type 2
diabetes, HbA1c $7% ($53 mmol/mol),
and a high risk for CVD (aged $50 years
with established CVD or chronic kidney
disease stage 3 or greater or $60 years
with at least one risk factor for CVD,
defined fully in the protocol available
as supplementary material to the pri-
mary publication [6]). Patients were
randomly assigned double-blind, 1:1 to
once-daily injections of liraglutide (1.8
mg or maximum tolerated dose) or pla-
cebo, both in addition to standard-of-
care treatment for type 2 diabetes and
other CV risk factors, with a follow-up
period of 3.5–5 years (6).
The primary end point was the time to
first occurrence of a major adverse CV
event (MACE), including CV death, non-
fatal myocardial infarction, or nonfatal
stroke (6). Secondaryendpoints included
the individual componentsof theprimary
composite end point and all-cause death
(6). Other variables assessed during the
trial included: HbA1c, body weight, waist
circumference, fasting lipids, systolic blood
pressure, diastolic blood pressure, pulse
rate, biochemical and hematological pa-
rameters, calcitonin levels, anti-liraglutide
antibodies, urinary albumin-to-creatinine
ratio (UACR), the occurrence of hypogly-
cemia, adverse events, and concomitant
medication use.
Mediation Analyses
Exploratory analyses were conducted to
divide the total effect of liraglutide on
time to first MACE, and other time-to-
event outcomes, into an indirect effect
(also known as mediated effect) and a
direct effect (also known as remaining
effect). The indirect effect may be inter-
preted as the difference in time to event
between liraglutide and placebo that
could be explained by a difference in
another variable such as body weight or
HbA1c, which we will refer to as the me-
diator. Thedirect effect is, in contrast, the
effect that remained after controlling for
the mediator.
Analyses were performed using meth-
ods based on a Cox proportional hazards
model, which we refer to hereafter as
Cox methods, and a new, more complex
method, termed the Vansteelandtmethod
(10).
Cox Methods
Preliminary analyses were performed
using two variants of a Cox proportional
hazards model to estimate the direct
effect:
1. Analysis including the change from
baseline in the potential mediator
over time as a time-dependent co-
variate. At any given time point, the
most recent change from baseline in
the mediator, before the occurrence
of the outcome in question, was in-
cluded as a covariate. Until the first
mediator assessment after baseline,
the changewas 0. This was one of two
approachesusedby Inzucchi etal. (11)
to evaluate mediated effects on CV
death in the BI 10773 (Empagliflozin)
Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus Patients
(EMPA-REG OUTCOME) trial.
2. Analysis including the updated mean
value of the potential mediator (be-
fore the occurrence of the outcome in
question), calculated as the trapezoi-
dal area under the curve divided by
time, as a time-dependent covariate.
This was the other approach used by
Inzucchi et al. (11) with the intention
of capturing the cumulative effect of
all prior values of the mediator on
the outcome, in contrast to the acute
effect in the first approach above.
These twoapproacheswereperformed
as separate Cox regression analyses for
each potential mediator with randomized
treatment as a factor and the baseline
mediator value as an additional covariate
to estimate the direct effect as a log
hazard ratio (HR). The total effect was
estimated using a model with only treat-
ment as a factor, and the indirect (me-
diated) effect was estimated as the
difference between total and direct
effects.
Vansteelandt Method
The Cox analyses have shortcomings in
that they may not capture the full com-
plexity of the mediator and prohibit
adequate control for confounding. Fur-
thermore, they do not immediately lend
themselves to a counterfactual inter-
pretation (conceiving outcomes in con-
ditions altered from those that were
observed) as used in the modern theory
of mediation analysis (12). As the main
approach for our mediation analysis, we
applied a new statistical method pro-
posed by Vansteelandt et al. (10) that
addresses these shortcomings and is tai-
lored for time-to-event end points with
repeatedly measured mediators.
With this new method, the direct
treatment effect was estimated as the
difference between probabilities of event-
free survival (i.e., proportions of patients
without any event) in liraglutide and
placebo groups, instead of an HR. It
involved estimation of the counterfac-
tual probability that a patient in the
liraglutide group would be event-free
at a given time if their mediator values
changed to the levels that would have
been seen if the patient had been as-
signed to placebo. Alternatively, thismay
be interpreted as the survival curve for
the liraglutide group after adjusting the
mediator values to match those obser-
ved in the placebo group. Similar to the
Coxmethodusing the updatedmean, the
Vansteelandt method is based on a dy-
namic model that incorporates new val-
ues of the mediator as they become
available over time. However, with the
Vansteelandt method, mediator values
are not summarized into a mean, but are
added to the model as separate cova-
riates. The method is therefore more
likely to detect a mediated effect if
present. All analyses undertaken allowed
adjustment for baseline covariates. How-
ever, the Vansteelandt method may also
adjust for postbaseline confounders, such
as concomitant medication, by including
themas covariates in themodels. Further
details of this method have been pub-
lished separately (10).
The direct effect was estimated as the
differencebetweenadjusted survival curve
for the liraglutide group (mediator values
adjusted to match those in the placebo
group) and the actual survival curve for
the placebo group. The actual curve was
estimated by the samemethod but using
each patient’s actual mediator values as
covariates.
To estimate the indirect (mediated)
effect, the adjusted survival curve for
the liraglutide groupwas comparedwith
the actual curve for the same group. The
total effect was estimated by comparing
the actual curve for the liraglutide group
with the actual curve for the placebo
group.
The percentage mediation was calcu-
lated as the ratio between the indirect
and total effects. Complete mediation
would be indicated by a percentage me-
diation of 100%. The percentage medi-
ation was evaluated and presented at
3 years because this time point corre-
sponds to the last scheduled visit, which
all patients should have attended. There-
after, the number of patients under
observation for MACE decreased over
time, leading to an increased statistical
uncertainty of the estimated survival
curves.A CI for the percentagemediation
was estimated using a bootstrap resam-
pling procedure. Because the calculation
was highly computer intensive, a CI was
only calculated for the strongest candi-
date for mediation.
Identifying Potential Mediators
Potentialmediators examined in allmeth-
ods includedcandidate variablesonwhich
liraglutide had a clear treatment effect
and that could be related to MACE
(HbA1c, body weight, UACR, confirmed
hypoglycemic episodes, sulfonylurea use,
and insulin use) and candidate mediators
on which liraglutide had a modest treat-
ment effect and that could be related to
MACE (systolic blood pressure and LDL
cholesterol) (Table 1). These previously
published treatment effects were eval-
uated atmonth 36 (6), but themediation
analyses undertaken in this study are
based on the mediator values indicated
in the preceding sections, such as the
value at 6 or 12 months, the most recent
value, or all values updated over time
before the event in question. Each can-
didate was analyzed separately using the
two Cox methods and the Vansteelandt
method to explore if it was a potential
mediator for MACE.
Additional analyses were performed
using the Vansteelandt method for the
candidate with the highest apparent de-
gree of mediation as the mediator:
1. Analysis of time to first MACE includ-
ing the other candidate mediators as
confounders.
2. On-treatment analysis of time to
first MACE (i.e., an analysis excluding
events occurring while the patient
was off treatment for .1 day). The
intentionof this analysiswas to remove
differences in treatment adherence (to
either liraglutide or placebo) among
patients, because treatment adher-
ence could influence both the medi-
ator and the risk ofMACE and thereby
act as a confounder. If such confound-
ing existed, the estimated percentage
mediation would be expected to be
less in the on-treatment analysis than
in the main analysis.
3. Analysis of time to first MACE with
reversed adjustment for themediator
(i.e., in which the survival curve for
the placebo group was estimated af-
ter adjusting their mediator values to
match those in the liraglutide group).
The purpose of this analysis was to
explore if the mediator might simply
be amarker of exposure to liraglutide.
If true, the adjusted survival curve for
the placebo groupwould be expected
to be close to the actual placebo
curve, indicating no mediation.
4. Analyses of time to all-cause death
and CV death.
RESULTS
In the LEADER trial, 9,340 patients were
randomized to liraglutide (N 5 4,668)
or placebo (N 5 4,672), in addition to
standard-of-care therapy, with a median
follow-up of 3.8 years and a median
exposure to studydrugof3.5years (6). To
begin this mediation analysis, the pub-
lished LEADER resultswere examined (6).
Several risk factors were improved in
patients in the liraglutide versus placebo
groups (Table 1) and hence were ana-
lyzed as potential mediators of the pre-
viously reported benefit of liraglutide
treatment for MACE (HR 0.87 [95% CI
0.78; 0.97]) (6).
Table 1—Potential mediators of the CV benefit with liraglutide identified from LEADER
Variable
Difference between liraglutide and
placebo groups (95% CI)
Difference between liraglutide and
placebo groups: z score
HbA1c, % ETD: 20.40 (20.45; 20.34)* 213.5
Body weight, kg ETD: 22.3 (22.5; 22.0)* 216.2
UACR ETR: 0.83 (0.78; 0.88)* 26.1
Rate of confirmed hypoglycemia during the trial Rate ratio: 0.81 (0.74; 0.88) 24.8
Systolic blood pressure, mmHg ETD: 21.2 (21.9; 20.5)* 23.3
LDL cholesterol ETR: 0.98 (0.96; 0.99)* 23.0
Patients who initiated insulin use during the trial, n (%) 1,336 (28.8) vs. 2,019 (43.2) d
Patients who initiated SU use during the trial, n (%) 349 (7.5) vs. 505 (10.8) d
ETD, estimated treatment difference; ETR, estimated treatment ratio; SU, sulfonylurea. *Change from baseline to 36 months (ETR was used when
the data were log-transformed, due to their known distributions).
Cox Methods to Determine Potential
Mediators of MACE
Mediation analyses using the Cox meth-
ods indicated amediation effect of HbA1c
(Table 2). While there was only a very
small mediation effect using the change
from baseline as a time-dependent co-
variate, analysis with the updated mean
indicated that HbA1c could be a substan-
tial mediator for the treatment effect of
liraglutide on MACE (Table 2). The same
analyses with the other potential medi-
ators demonstrated at most a small ef-
fect size, with the possible exception for
UACR (Table 2).
Vansteelandt Method to Determine
Potential Mediators of MACE
Mediation analysis using the Vansteelandt
method (10) also indicated that HbA1c was
the most promising candidate among
those studied as a potential mediator
(Fig. 1 and Table 3). When adjusted for
HbA1c, the survival curve (proportion of
patients without MACE) for patients ran-
domized to liraglutide treatment shifted
down toward the placebo curve. This
indicated a reduced CV benefit in the
liraglutide group when the difference in
HbA1c between the liraglutide and pla-
cebo groups was modeled as a mediator
for the MACE results (Fig. 1 and Table 3).
A potential small mediation effect was
observed with UACR (Table 3), but the
estimatedmediation was relatively small
for theother candidates (,20%) (Table3).
The estimated contribution of HbA1c
as a mediator to the effect of liraglutide
on MACE at 3 years was 82.0% (95% CI
11.7; 449.3), with the direct effect of
liraglutide accounting for the remaining
18%of the total observed CVbenefit (Fig.
1 and Table 3). Because there was no
clear mediation through any other can-
didate variable, none of them would be
likely to confound themediation through
HbA1c. Nevertheless, the analysis was
repeated with body weight, UACR, sys-
tolic blood pressure, LDL cholesterol,
confirmed hypoglycemic episodes, sulfo-
nylurea use, and insulin use included as
confounders in the model. The indirect
effect of liraglutide on MACE mediated
by HbA1c was estimated to be 69.2%,
which is consistent with the analysis
without confounders considering the un-
certainty in the estimates (Supplemen-
tary Fig. 1).
On-treatment analysis (excluding MACE
that occurred when a patient was off
treatment) showed a slightly stronger
mediation effect for HbA1c of 93%
than the 82% observed in the first
Vansteelandt mediation analysis (with-
out confounders) (Supplementary Fig. 2).
The reversed adjustment analysis showed




All-Cause Death and CV Death
The same types of analyses were applied
to all-cause death and CV death. The
effects of liraglutide on these end points
in LEADER appeared to be mediated by
HbA1c to some extent (Supplementary
Fig. 4).
CONCLUSIONS
These mediation analyses of the LEADER
trial data, with the Cox methods and the
new Vansteelandt method, suggest that
HbA1c could be a significant mediator of
theCVbenefits observedwith liraglutide.
There was no evidence for a mediation
effect with any other candidates that
Table 2—Cox modeling for mediation of time to first MACE with liraglutide versus placebo by HbA1c, body weight, UACR, SBP,
LDL cholesterol, confirmed hypoglycemic episodes, SU use, and insulin use, assessed using two approaches
Analysis
Risk of MACE with liraglutide vs.
placebo, HR (95% CI)
Percentage mediation
(95% CI)†
Total treatment effect (primary LEADER analysis) 0.868 (0.778; 0.968) d
Treatment effect adjusted for:
HbA1c
Change as time-dependent covariate 0.880 (0.787; 0.984) 9.9 (211.4; 59.0)
Updated mean as time-dependent covariate* 0.920 (0.820; 1.033) 41.1 (8.6; 161.0)
Body weight
Change as time-dependent covariate 0.860 (0.770; 0.962) 27.4 (243.9; 13.3)
Updated mean as time-dependent covariate* 0.864 (0.772; 0.968) 23.9 (247.0; 26.2)
UACR
Change as time-dependent covariate 0.899 (0.804; 1.004) 21.9 (7.5; 106.4)
Updated mean as time-dependent covariate* 0.907 (0.812; 1.013) 28.6 (12.3; 132.8)
Confirmed hypoglycemia
Change as time-dependent covariate 0.868 (0.778; 0.967) 20.3 (24.5; 2.2)
Updated mean as time-dependent covariate* 0.868 (0.778; 0.968) 20.1
SBP
Change as time-dependent covariate 0.874 (0.784; 0.975) 5.2 (20.6; 21.2)
Updated mean as time-dependent covariate* 0.877 (0.787; 0.979) 7.7 (0.2; 31.7)
LDL cholesterol
Change as time-dependent covariate 0.869 (0.778; 0.970) 0.6 (24.2; 7.7)
Updated mean as time-dependent covariate* 0.869 (0.778; 0.970) 0.7 (24.2; 8.8)
Insulin use
Change as time-dependent covariate 0.889 (0.796; 0.993) 16.9 (3.1; 85.7)
Updated mean as time-dependent covariate* 0.894 (0.801; 0.998) 20.7
SU use
Change as time-dependent covariate 0.861 (0.772; 0.960) 25.6 (225.2; 20.3)
Updated mean as time-dependent covariate* 0.865 (0.776; 0.965) 22.3
SBP, systolic blood pressure; SU, sulfonylurea. *Calculated as the trapezoidal area under the curve divided by time. †CI for the percentage mediation
was estimated using a bootstrap resampling procedure.
were assessed in the trial, with the pos-
sible exception of UACR. A mediation
effect of HbA1c on mortality was also
observed. However, it is important to
note that these analyses cannot distin-
guish between the possibilities that
HbA1c could be amediator or amarker of
unmeasured factors that are also af-
fected by treatment with liraglutide and
that themselves affect CV outcomes. For
example, a large change in HbA1c could
be indicative of adherence to treatment,
including concomitantmedications. Con-
trary to the hypothesis that HbA1c could
be acting as a marker of treatment ad-
herence, an on-treatment analysis showed
treatment adherence was unlikely to be
a confounding factor, as the percentage
mediation was not reduced compared
with themain analysis. A related hypothesis
is that HbA1c could be acting as a marker
of exposure to liraglutide specifically, but
this was not supported by the reversed
adjustment analysis in which the asso-
ciation between HbA1c and CV outcomes
was also apparent in the placebo group.
Modern CV outcome trials with the
GLP-1 RA lixisenatide, dipeptidyl pepti-
dase 4 inhibitors (alogliptin, saxagliptin,
and sitagliptin), and insulin (insulin glar-
gine), on a background of standard-of-
care therapy, showed CV safety but
failed to show benefits on CV outcomes
despite improvements in HbA1c in the
active- versus placebo-treatment groups
(13–17). More recently, results from
other CV outcome trials have shown
CV benefits for the sodium–glucose
transporter 2 (SGLT2) inhibitors empa-
gliflozin and canagliflozin and the GLP-1
RAs liraglutide, semaglutide, albiglutide,
and dulaglutide (6,18–22). In others, non-
significant trends for reductions in CV
events (MACE) were reported (for dapa-
gliflozin: SGLT2 inhibitor; for exenatide
[once weekly] and semaglutide [oral]:
GLP-1 RAs) (23–25). Changes in HbA1c
from baseline with the study treatment
versus placebo in these more recent trials
ranged from20.36% to21.0% (6,18–25),
which were marginally larger than changes
in the previous trials that showed no CV
benefits (range of changes in HbA1c:20.2%
to20.36%[13–17]). Thesemodest changes
inHbA1cacrossallof thesetrialswithvarying
CV outcome results (including variation
within drug classes) suggest that mecha-
nisms other than reductions in HbA1c
account for the CV benefits with liraglu-
tide, semaglutide, albiglutide, dulaglutide,
empagliflozin, and canagliflozin (6,13–25).
For example, within Harmony Outcomes,
there was a relatively small (20.5%) dif-
ference in HbA1c between albiglutide
and placebo at 16 months, but a rela-
tively large (22%) risk reduction in MACE
(22).
Epidemiological data support the as-
sociation between HbA1c and CV and
mortality outcomes (26,27). Data from
.250,000 people in the Swedish Na-
tionalDiabetesRegister found thatHbA1c
was a strong predictor of all-cause death,
myocardial infarction, stroke, and heart
failure (27). These epidemiological data
appear to be supported by a meta-
analysis using results from early CV out-
come trials of intensive glucose control
in patients with type 2 diabetes (UK
Prospective Diabetes Study [UKPDS],
Prospective Pioglitazone Clinical Trial
in Macrovascular Events [PROactive], Ac-
tion in Diabetes and Vascular Disease:
Table 3—Vansteelandt modeling for mediation of time to first MACE with liraglutide versus placebo: by HbA1c, body weight,
UACR, SBP, LDL cholesterol, confirmed hypoglycemic episodes, SU use, and insulin use
Variable
Estimated proportion of patients without MACE at 3 years
Percentage mediation (95% CI)Liraglutide
Liraglutide, adjusted for
candidate mediator Placebo
HbA1c 0.893 0.881 0.878 82.0 (11.7; 449.3)
Body weight 0.893 0.891 0.879 14.3
UACR 0.892 0.888 0.880 33.3
Confirmed hypoglycemia 0.893 0.892 0.878 6.7
SBP 0.893 0.891 0.878 13.3
LDL cholesterol 0.893 0.893 0.879 0.0
Insulin use 0.892 0.890 0.878 14.3
SU use 0.893 0.891 0.878 13.3
SBP, systolic blood pressure; SU, sulfonylurea.
Figure 1—Probability of no MACE occurring in patients treated with liraglutide and placebo and
with adjustment for HbA1c as a candidate mediator using the Vansteelandt method.
Preterax and Diamicron MR Controlled
Evaluation [ADVANCE], Veterans Affairs
Diabetes Trial [VADT], and Action to
Control Cardiovascular Risk in Diabetes
[ACCORD]dall trials with varying results
for CV benefits) showingmodest benefits
for CV outcomes (28). Taken as a whole,
the data strongly suggest that the choice
of therapies used to reduce HbA1c, and not
just HbA1c reduction itself, has an im-
portant impact on CV outcomes.
For SGLT2 inhibitors, it has been
proposed that hemodynamic effectsd
reducing blood pressure and intravascular
volumedand diuretic effects could be
underlyingmechanisms for theCVbenefits
(29,30). These hypotheses are supported
by a mediation analysis of data from
EMPA-REG OUTCOME, which identified
hematocrit and hemoglobin, markers of
effects on plasma volume, as potential
key mediators for the effects of empagli-
flozin on CV death, with smaller media-
tion effects attributed to renal function
and glycemic control (11). Though HbA1c
appears to have a smaller mediation
effect relative to hematocrit and hemo-
globin for empagliflozin, it was identified
as a potential mediator in the EMPA-REG
OUTCOME trial based on simple Cox
methods (11). The EMPA-REGOUTCOME
analyses showed that change from base-
line HbA1c mediated 3% of the effect of
empagliflozin on CV death, while updated
mean HbA1c mediated 23% of the effect,
suggesting a greater impact of chronic
exposure to elevated HbA1c during the
trial (11).Similarly,ouranalysesofLEADER
data using the same two Cox methods
(but with the primary end point of time
to first MACE) showed little effect of
change as a time-dependent covariate,
but a larger mediation effect of updated
mean HbA1c.
The percentage mediation of HbA1c in
LEADER is difficult to compare across dif-
ferent analysis methods that we used.
However, the Cox analyses appeared to
support the main Vansteelandt mediation
analyses in identifying HbA1c as the main
candidate for a mediator, among those
analyzed, of the effect of liraglutide on CV
outcomes.
The occurrence of hypoglycemia was
shown tobeassociatedwith an increased
risk of CV events in LEADER (31). How-
ever, beyondHbA1c andUACR, little to no
mediation effect was identified for the
other candidates analyzed, including hy-
poglycemia. We therefore speculated
that factors such as reduction in hypo-
glycemia combined with a reduction in
HbA1c with liraglutide might explain the
apparent mediation by HbA1c. However,
results were largely unchanged when
hypoglycemia was included as a con-
founder (along with other candidates in
the mediator model).
Ourmediation analyseswerepost hoc,
and, in contrast to the primary analysis of
the trial, they are not protected against
confounding through patient randomi-
zation. The inability to distinguish true
mediators from markers is the key lim-
itation of this present and other pub-
lished mediation analyses. Our analyses
are limited by the trial data; only candi-
date mediators that were examined or
measured during the trial could be eval-
uated. Future trials may help to allow
examinationof awider range of potential
mediators through collection of biobank
samples. However, even in a large trial
like LEADER, it was not possible to esti-
mate the percentage mediation with
precision. The estimates were subject to
substantial uncertainty reflected by the
wide CI for the percentage mediation
through HbA1c. It is important to note
that there is uncertainty in the total
treatment effect of liraglutide in the
primary analysis that constitutes the
starting point for this mediation analysis
and that, based on the 95% CI, could
be a 3–22% reduced risk of MACE com-
pared with placebo (6). Furthermore,
although the Vansteelandt method has
the advantage that it improves the ability
to detect a mediated effect, it does not
allow us to distinguish what components
of the mediator might contribute to the
mediated effect (i.e., whether it is the
early response, the average level over
time within patients, the variability
within patients, or a combination of
several such components). Also, this
analysis was limited to MACE, which is
comprised of several individual CVDs, all
of which have potentially different un-
derlying pathologies and therefore me-
diators. These limitations emphasize that
the results should be interpreted with
caution and only be considered hypoth-
esis generating.
In summary, thesemediation analyses
have identified HbA1c as a potential
mediator of the CV effects of liraglutide.
Wedidnot identify anymediation effects
for less well-studied but possible can-
didate mediators, which are also risk
factors for CV events, including weight
and hypoglycemia. Similar to all other
mediation analyses, we cannot necessarily
infer causality, and whether HbA1c is a
marker of an unmeasured factor or a true
mediator remains a key question. Based
on existing evidence, we consider it un-
likely that HbA1c is a true mediator of the
CV benefit observed with liraglutide, and
this finding warrants further investigation.
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